National Medical Products Administration
Forxiga Receives Green Light in China to Mitigate Cardiovascular Mortality and Hospitalization in Adults Battling Symptomatic Chronic Heart Failure
Anika Sharma
China’s National Medical Products Administration (NMPA) has granted approval to Forxiga (dapagliflozin) as a groundbreaking solution in the fight against ...
Xigduo XR Receives Approval in China for the Treatment of Type II Diabetes in Adults
SG Tylor
Source – AstraZeneca On June 27, 2023, AstraZeneca’s Xigduo XR, a once-daily fixed-dose combination of dapagliflozin and metformin hydrochloride extended-release, ...
